Open AccessDual Antiplatelet Drug Resistance Is a Risk Factor for Cardiovascular Events after Percutaneous Coronary Intervention
Author(s) -
Boris Ivandic,
Mareike Sausemuth,
Hesham Ibrahim,
Evangelos Giannitsis,
Meinrad Gawaz,
Hugo A. Katus
Publication year - 2009
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2008.115089
Subject(s) - medicine , clopidogrel , percutaneous coronary intervention , conventional pci , clinical endpoint , cardiology , myocardial infarction , pharmacodynamics , loading dose , ticlopidine , hazard ratio , aspirin , risk factor , pharmacology , pharmacokinetics , clinical trial , confidence interval
Nonresponsiveness to clopidogrel and acetylsalicylic acid (ASA), a frequent result of platelet aggregometry studies, has unclear clinical and prognostic significance.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom